logo

For the Inventor, By the Inventor

Milan, Italy

Mario Grugni

This inventor holds 10 USPTO granted patents and 1 published patent application. Top assignees: Smithkline Beecham Corporation, Smithkline Beecham Farmaceutici, Glaxosmithkline LLC. Active years: 1998-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mario Grugni. Retrieved from https://idiyas.com/inventor/mario-grugni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 40.0

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • Verbania, IT (2001 - 2004)
  • Milan, IT (2004 - 2006)
  • Domodossola, IT (1998 - 2009)

Company Filing History:

goldMedal4 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal2 out of 6 
 
Smithkline Beecham Farmaceutici
 patents
bronzeMedal1 out of 358 
 
Glaxosmithkline LLC
 patents
4. 1 out of 1 
 
Smithkline Beecham Farmaceutica S.p.a.
 patent
5. 2 out of 834,513 
Other
 patents

Years Active: 1998-2009

Loading Chart...
10 patents (USPTO):Explore Patents
1. 7482458 - Quinoline derivatives (2009-01-27),
2. 7115633 - Benzosuberonylpiperdine compounds as analgesics (2006-10-03),
3. 6969724 - Compounds (2005-11-29),
4. 6780875 - Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists (2004-08-24),
5. 6743804 - Quinoline derivatives as NK3 antagonists (2004-06-01),
6. 6613770 - Quinoline derivatives as NK-2 and NK-3 receptor ligands (2003-09-02),
7. 6608083 - Quinoline derivatives(2) (2003-08-19),
8. 6355654 - Salts of quinoline derivatives as NK3 antagonists (2002-03-12),
9. 6277862 - Quinoline derivatives (2001-08-21),
10. 5811553 - Quinoline derivatives(2) (1998-09-22),

Title: The Innovative Contributions of Inventor Mario Grugni

Introduction

Mario Grugni is a prolific inventor based in Milan, Italy, with a remarkable portfolio consisting of ten patents. His work primarily focuses on advancements in medical chemistry, providing innovative solutions for various health-related issues. With a commitment to improving therapeutic options, Grugni has made significant strides in the field of pharmaceuticals.

Latest Patents

Among his latest contributions, Grugni developed quinoline derivatives that function as NK receptor antagonists of specific formulas. These compounds show promise in treating conditions such as pulmonary disorders, central nervous system disorders, and neurodegenerative diseases. Additionally, he designed benzosuberonylpiperdine compounds that serve as analgesics. The intricate formulas involve various derivatives, showcasing the complexity and innovation behind his work. These compounds engage with the ORL-1 receptor and present potential therapeutic applications.

Career Highlights

Mario Grugni has had a distinguished career, having worked with notable companies like SmithKline Beecham Corporation and SmithKline Beecham Farmaceutici S.p.a. His experience in leading pharmaceutical firms has enabled him to cultivate his expertise in drug development and innovation.

Collaborations

Throughout his career, Grugni has collaborated with esteemed colleagues such as Carlo Farina and Luca Francesco Raveglia. These partnerships have contributed to the success of his inventions and reflect his ability to work effectively within a team to advance scientific research.

Conclusion

Mario Grugni's dedication to innovation in the pharmaceutical industry has resulted in significant contributions that enhance therapeutic options for patients. As he continues to develop novel compounds and collaborate with fellow researchers, his impact on the field is certain to grow, driving forward the boundaries of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…